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Hypoglycemia is a common finding in both daily clinical practice and acute care 
settings. The causes of severe hypoglycemia (SH) are multi-factorial and the major 
etiologies are iatrogenic, infectious diseases with sepsis and tumor or autoimmune 
diseases. With the advent of aggressive lowering of HbA1c values to achieve opti-
mal glycemic control, patients are at increased risk of hypoglycemic episodes. Iat-
rogenic hypoglycemia can cause recurrent morbidity, sometime irreversible neuro-
logic complications and even death, and further preclude maintenance of euglycemia 
over a lifetime of diabetes. Recent studies have shown that hypoglycemia is asso-
ciated with adverse outcomes in many acute illnesses. In addition, hypoglycemia 
is associated with increased mortality among elderly and non-diabetic hospitalized 
patients. Clinicians should have high clinical suspicion of subtle symptoms of hy-
poglycemia and provide prompt treatment. Clinicians should know that hypogly-
cemia is associated with considerable adverse outcomes in many acute critical ill-
nesses. In order to reduce hypoglycemia-associated morbidity and mortality, timely 
health education programs and close monitoring should be applied to those diabet-
ic patients presenting to the Emergency Department with SH. ED disposition strat-
egies should be further validated and justified to achieve balance between the ben-
efits of euglycemia and the risks of SH. We discuss relevant issues regarding 
hypoglycemia in emergency and critical care settings.
Key Words:    Hypoglycemia, hyperglycemia, diabetes mellitus, emergency medi-
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INTRODUCTION
Hypoglycemia is a common finding in both daily clinical practice and acute care 
settings. The prevalence of hypoglycemic episodes remains high following the 
prevalence of diabetes.1 The causes of severe hypoglycemia (SH) are multi-facto-
rial and the major etiologies are iatrogenic, infectious diseases with sepsis, tumor 
or related to autoimmune diseases. Reduction of blood glucose levels among pa-
tients with diabetes mellitus (DM) has been shown to reduce cardiovascular com-
plications.2 The advent of aggressive lowering of HbA1c values causes an in-
creased risk of hypoglycemic episodes in these patients.3,4 Iatrogenic hypoglycemia Hypoglycemia Revisited 
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be self-treated. SH is defined as event requiring the assis-
tance of another person to actively administer carbohydrate, 
glucagon, or other resuscitative actions. These episodes 
may be associated with sufficient neuroglycopenia to in-
duce seizure or coma.21 A serum glucose cut-off value of 
40-50 mg/dL has been used to define SH.12,22,23
Incidence 
Patients with T1DM could experience an average two epi-
sodes of symptomatic hypoglycemia per week.24 In general, 
SH appears to be less frequent in insulin-treated patients with 
T2DM than with T1DM.10,25,26 The incidence of hypoglyce-
mia episodes in insulin-treated patients with T2DM was 
0.44 episodes per patient year; 16.5 of patients had experi-
enced at least one event.27,28 The annualized rate of hypo-
glycemia was 2.7% to 3% in patients treated with intensive 
insulin therapy targeting HbA1c of 6-6.5%, compared to 
1% to 1.5% with standard treatment.29,30 Approximately 7% 
of patients admitted to the Emergency Department (ED) with 
complaints of altered mental status have hypoglycemia. Up 
to 20% of patients with diabetes treated with insulin or anti-
diabetic agents (ADAs) had hypoglycemia-related symp-
toms that required ED evaluation and treatment.31
Clinical presentations 
Hypoglycemic symptoms in adults can be divided into auto-
nomic, neuroglycopenic and non-specific groups. Clinical 
presentations of hypoglycemia are listed in Table 1. Auto-
nomic symptoms tend to occur first at blood glucose levels 
of around 59-65 mg/dL; neuroglycopenic symptoms occur at 
blood glucose levels of about 47-54 mg/dL; finally, cognitive 
functions deteriorate at a slightly lower blood glucose lev-
els.32,33 Symptoms of hypoglycemia may differ with increas-
ing duration of diabetes but can also be affected by a period 
of recent metabolic change. Hypoglycemic symptoms can be 
nonspecific, including weakness, unsteadiness, sleepiness, 
faintness, and a feeling of tense-tiredness. Many people feel 
sad and unhappy with overt pessimism and negative feelings. 
Blurred vision and reading difficulties are common during 
insulin-induced hypoglycemia in normal subjects and in in-
sulin-treated patients. Hypoglycemic symptoms are also age-
specific; neurological symptoms are predominant in elderly 
patients, whereas features of behavioral changes are more 
common in children.34 History of morning headache or hang-
over, poor sleep quality, vivid dreams or nightmares, profuse 
sweating in bed and restless behavior (found by their spouses 
or partners) during sleep are symptoms that may suggest 
can cause recurrent morbidity, sometime irreversible neuro-
logic complications and even death as well as a vicious cy-
cle of recurrent hypoglycemia, and further preclude mainte-
nance of euglycemia over a lifetime of diabetes.5-9 The 
Action to Control Cardiovascular Risk in Diabetes (AC-
CORD) study found that, compared to patients with con-
ventional glucose control, patients under tight glycemic 
control had an excess mortality rate, particularly in those 
with multiple risk factors or known coronary artery disease. 
Intensive therapy was discontinued after a median follow-
up of 3.4 years, because of the observed significant increase 
in risk of death from any cause and from cardiovascular 
causes in this group. Excess mortality during intensive ther-
apy in the ACCORD study was attributed to treatment-as-
sociated hypoglycemia.10,11 Recent studies have shown that 
hypoglycemia is associated with adverse outcomes in many 
acute illnesses.12-16 In addition, hypoglycemia is associated 
with increased mortality in elderly and non-diabetes hospi-
talized patients.17 However, hypoglycemia is not an inde-
pendent predictor for mortality in a multivariate analysis, 
indicating that it is only a marker and not itself associated 
with long term prognosis. Low fasting plasma glucose lev-
els are also associated with high mortality.17-19 
We focused our review on recent advances and conceptu-
al evolutions regarding hypoglycemia in acute care settings 
using a multidisciplinary approach. This is not intended to 
be a systemic review; we focus on relevant issues regarding 
hypoglycemia in acute care settings.
OVERVIEW
　　　
Hypoglycemia occurs frequently in both patients with type 1 
DM (T1DM) and type 2 DM (T2DM). It significantly affects 
patients’ daily lives, and increases risk of serious injury, and 
is often a limiting factor in achieving physiologic glucose 
levels with diabetic therapy. Hypoglycemia should be proven 
by fulfillment of the Whipple’s triad: 1) symptoms consistent 
with hypoglycemia; 2) a low plasma glucose concentration 
measured with a precise method; and 3) relief of the present-
ing symptoms after the plasma glucose level is raised.20 
Definition of hypoglycemia
The lower limit of the fasting plasma glucose concentration 
is normally approximately 70 mg/dL. Generally, the bio-
chemical threshold for hypoglycemia is about 70 mg/dL.21 
Mild hypoglycemia can be defined as an episode that can Shih-Hung Tsai, et al.
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ing during or shortly after exercise, or delayed by 6-15 
hours after activity.38,39 Alcohol consumption can cause pro-
longed, unexpected hypoglycemia in people with T2DM, 
particularly in those taking ADA.40 Non-islet cell tumor hy-
poglycemia is a rare but well-recognized phenomenon. He-
patocellular carcinoma can present with SH.41,42 Hemato-
logical malignancies can present as a combination of lactic 
acidosis and hypoglycemia.43,44 In critically ill patients, fe-
male gender, diabetes, mechanical ventilation, continuous 
veno-venous hemodialysis and prolonged intensive stays 
are associated with increased risk of hypoglycemia.12 Risk 
factors for the development of hypoglycemia in patients 
with diabetes are listed in Table 2.
Insulin and insulin secretagogues
The use of peakless insulin analogues can reduce the inci-
dence of hypoglycemia.45 Reducing the insulin dose by com-
bining it with another ADA can lead to a lower incidence of 
hypoglycemia than insulin treatment alone.46 About 20% of 
patients prescribed sulphonylureas experience one or more 
episodes of hypoglycemia, and each year more than 1% will 
have an episode of SH.47 The metabolites of glyburide are 
metabolically active and can accumulate in patients with re-
nal insufficiency. In contrast, the metabolites of glypizide and 
glimepiride are largely inactive.48 Thus glyburide is associ-
ated with the highest risk of hypoglycemia and can cause 
episodes to be prolonged, while there is a lower risk of hy-
poglycemia in patients treated with glimepiride and glypi-
zide.49-51 Polypharmacy with additional drugs increases the 
risk for drug interactions.52 Renal insufficiency and defi-
ciencies of diabetes care are commonly neglected crucial 
contraindications of sulphonylureas and contributed to risk 
of SH in geriatric patients.53
Other anti-diabetic agents
Metformin, thiazolidinediones and dipeptidyl peptidase-4 
(DPP-4) inhibitors appear to be appropriate oral options for 
minimizing the risk of hypoglycemia.54 Metformin acts by 
increasing insulin sensitivity and reducing hepatic glucose 
output and does not increase plasma insulin levels, thereby 
posing a low risk of hypoglycemia when used as monother-
apy; however, the risk of hypoglycemia may be significant-
ly increased when metformin is added to exogenous insulin 
or insulin secretagogues.55 Glitazones work by activating 
peroxisome proliferator-activated receptor γ and sensitizing 
tissues such as the liver, skeleton muscle and adipose tissue 
to insulin. Glitazone monotherapy and glitazone-metformin 
nocturnal hypoglycemia. Sleepwalking (somnambulism) has 
also been reported during nocturnal hypoglycemia.35 
Tight glycemic control is associated with increased risk 
of motor vehicle crashes; history of SH and later age of dia-
betes diagnosis are significant risk factors.36
Risk factors 
Patients 
Impaired hypoglycemia awareness, old age, longer duration 
of diabetes and insulin therapy increase the risk of hypogly-
cemia. Infection or its sequelae may also increase the risk of 
SH.37 For insulin-treated patients, exercise increases the risk 
of hypoglycemia. This risk may either be immediate, mean-
Table 1. Clinical Presentations of Hypoglycemia
Symptoms  Complaints
Autonomic
Hunger
Pallor
Palpitation Pounding heart, rapid heartbeat
Shaking Trembling
Sweating
Neuroglycopenic
Confusion Slowed thinking
Drowsiness
Lightheaded, visual disturbance, 
  blurred or double vision
Diplopia
Hemiparesis
Incoordination  Poor concentration
Odd behavior Restlessness
Speech difficulty Slurred speech
Seizure
Non-specific/behavioral/miscellaneous
Behavioral Anger, irritability, denial, sleepwalking
General malaise
Headache Nocturnal headache
Nausea
Nervous tense
Tingling lips
Table 2. Risk Factors for Hypoglycemia
Advanced age  Intercurrent illness
Alcohol consumption Malnutrition
Autonomic neuropathy Polypharmacy
Adrenergic-blocking agents Renal insufficiency
Cognitive impairment Sedative 
Endocrine deficiencies Secretagogues/insulin
Hypoglycemia unawareness  Tight glycemic control
Hepatic dysfunction
HypothyroidismHypoglycemia Revisited 
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fractory ventricular dysrhythmia.72,73
Who should be admitted to the hospital? 
The patients’ response to treatment, etiology of hypoglyce-
mia, existing comorbid conditions and social situation are 
factors that need to be considered when determining dispo-
sition.74 However, recommendations regarding disposition 
of patients with diabetes presenting with SH are generally 
based on retrospective studies, practice patterns, anecdote, 
and medical “common sense”; these suggestions lack sup-
port from validated studies.9,74 A single massive overdose of 
insulin glargine or sulphonylurea can cause unexpected 
prolonged hypoglycemia. Sulphonylureas can cause refrac-
tory and prolonged hypoglycemia and are the primary ADA 
associated with hypoglycemia. Higher admission rates are 
also observed in patients with abnormal laboratory findings 
including hypokalemia, hyperkalemia, leukocytosis, pyuria 
and either newly diagnosed or pre-existing renal failure.75 
The accumulated recurrent hypoglycemia rates have been 
identified as ranging from 6.1% to 14.7%, depended on the 
study population and settings.37,76-78 Nearly 32% of patients 
who were admitted to the hospital for SH developed recur-
rent hypoglycemia (RH). Patients with T2DM who present-
ed at the ED with SH as well as certain risk factors, includ-
ing loss of a recent meal, coronary artery disease, infection, 
and poor renal function were associated with increased risk 
of developing RH.37 A ‘response-to-treatment’-based strate-
gy was indicated to be useful in determining the ED dispo-
sition of diabetic patients presenting with SH. In one study, 
the initial serum glucose levels, therapeutic responses to 
glucose replacement and changes in serum glucose over 
time (mg/dL/hour) were retrospectively evaluated.79 Thera-
peutic responses to glucose replacement and changes in se-
rum glucose levels over time can differentiate patients with 
RH and overshoot hyperglycemia (OH) from those with fa-
combination have a lower risk of hypoglycemia than sul-
phonylureas monotherapy or sulphonylureas-metformin 
combinations.56,57 DPP-4 increases glucagon-like peptide 1 
levels and lowers blood glucose levels via stimulation of in-
sulin, only at meals or in the presence of elevated blood glu-
cose concentrations and inhibition of glucagon secretion. 
The risk of hypoglycemia is much lower than with sulpho-
nylureas.58 Monotherapy with α-glucosidase inhibitor has 
not been reported to cause hypoglycemia, but caution is war-
ranted in concurrent use of prandial insulin or insulin secre-
tagogues. Mismatching between peak serum glucose levels 
and peak prandial insulin levels may occur due to delayed 
carbohydrate absorption from the gut secondary to the ef-
fects of α-glucosidase inhibitor.59 
Other drug-induced hypoglycemia
The most commonly reported medications to be associated 
with hypoglycemia are quinolones, pentamidine, quinine, 
angiotensin-converting enzyme inhibitors and beta-adrener-
gic blockers.60 Severe hypoglycemia with inappropriately 
high levels of insulin and c-peptide has been found in pa-
tients treated with quinolones with or without sulphonyl-
ureas.61,62 Beverages such as tonic water can contain quinine 
and have been reported to cause hypoglycemia.63 Gatifloxa-
cin, quinine and disopyramide can stimulate insulin release 
by inhibiting the pancreatic β-cell ATP sensitive K chan-
nels.64-66 In users of glipizide or glyburide; drug-drug inter-
actions are evident with ciprofloxacin (in glyburide users 
only), clarithromycin, co-trimoxazole, fluconazole, and le-
vofloxacin.67 Trimethoprim can induce CYP2C8 inhibition, 
thus increasing the plasma concentration of repaglinide.68 
Concurrent use of sibutramine and sedatives was reported 
to have caused SH in a young woman with low body mass 
index.69 Medications that can potentiate the development of 
hypoglycemia are summarized in Table 3.
Who should have blood glucose checked and when? 
In patients who have altered consciousness, focal neurolog-
ic deficit or seizure attack, blood glucose level should be 
checked immediately. Hypoglycemia is one of the most 
common stroke mimics.70 Determination of blood glucose 
is one of the key procedures in the acute management pro-
tocol of acute ischemic stroke.71 Therefore, all patients pre-
senting with stroke symptoms should have their glucose 
measured to exclude hypoglycemia. Although debate re-
mains, hypoglycemia is one of the differential diagnoses of 
the “6H/6T” for pulseless electrical activity/asystole and re-
Table 3. Drugs that can Potentiate the Development of Hy-
poglycemia 
Beta-blockers
Disopyramide
Pentamidine
Quinine
Quinolone
Sulphonylurea
Salicylates
Sulfonamide
Sibutramine
TrimethoprimShih-Hung Tsai, et al.
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tients. It can be given 1 mg intramuscularly or subcutane-
ously. The effect is transient and patients should be instruct-
ed to eat to restore glycogen stores. 
Administration of glucose or glucagon in patients with 
sulphonylurea-induced hypoglycemia may be unsatisfied 
because these antidotal approaches are associated with fur-
ther exacerbation of insulin release by glucose and glucagon, 
leading to only temporary beneficial effects and later RH.82,83 
Octreotide can be safely and effectively used in treatment 
of sulphonylurea-induced hypoglycemia in patients with 
congestive heart failure and renal failure by adhering to dos-
ing guidelines and close monitoring.84,85
CARDIOLOGY
 
Acute coronary syndrome
Hyperglycemia is associated with increased mortality rates 
in patients who are diagnosed upon admission with acute 
myocardial infarction (AMI) and unstable angina.86 Howev-
er, in healthy individuals and patients with T1DM, acute hy-
poglycemia can result in complex vascular effects including 
activation of prothrombotic, proinflammatory, and pro-ath-
erogenic mechanisms. Moderate hypoglycemia acutely in-
creases the circulating levels of plasminogen activator in-
hibitor, vascular endothelial growth factor, vascular adhesion 
molecules, interleukin-6, and markers of platelet activa-
tion.87 In T2DM patients with coronary artery disease, hy-
poglycemic episodes are associated with depressed heart 
rate variability; however, beta-blocking agents are able to 
contrast this relationship.88 Hypoglycemia is associated with 
increased short-term mortality in patients hospitalized with 
AMI, but this risk is confined to patients who develop hy-
poglycemia spontaneously. Hypoglycemia that occurs after 
initiation of insulin therapy is not associated with a higher 
risk of mortality and may not be a direct mediator of ad-
verse outcomes in AMI patients.14,15 
Hypertension, cardiac dysrhythmia and QT 
prolongation 
By using continuous glucose monitoring system and 24-
hour electrocardiographic monitoring, a close temporal re-
lationship can be found between hypoglycemia and elevat-
ed blood pressure; nocturnal hypoglycemia is found to be 
associated with QTc prolongation and cardiac rate/rhythm 
disturbances in ambulant patients with T1DM.89,90 Since car-
diovascular disease and all-cause mortality is closely linked 
vorable glucose patterns during the first 48 h after presenta-
tion in the ED with SH. Using a cut-off value of 14.6 mg/
dL/hr for changes in serum glucose levels over time, the 
sensitivity and specificity values for the development of 
RH were 78.9% and 64.4%; for the development of OH, 
using a cut-off value of 28.7 mg/dL/hr achieved sensitivity 
and specificity values of 85.5% and 78.8%. Nearly 24% of 
diabetic patients who presented to the ED with SH actually 
had OH during hospitalization. These patients still required 
intensive serum glucose monitoring and ADA adjustment 
and had a similarly prolonged stay in the hospital. This is 
presumably due to multiple factors. Such factors include 
underlying complex interactions between triggering events, 
stress responses and the effects of counter-regulatory hor-
mones. Additional potential contributing elements to pro-
longed hospital stay include recently increased dosages of 
ADA for poorly controlled hyperglycemia, severe infec-
tions, evolutionary chronic renal insufficiency, heart failure 
and polypharmacy.79 However, this ‘response-to-treatment’ 
disposition strategy should be further validated in prospec-
tive studies. Without further study, we still recommend that 
a longer ED observation or admission is needed for patients 
who have increased risk of RH, including unsatisfactory re-
sponse to treatment, multiple comorbidities, the use of sul-
phonylureas or long-acting insulin preparations, poor oral 
intake, and those with concurrent infection or impaired re-
nal or liver function.
Management
Self-treatment by ingestion of glucose tablets (the commonly 
recommended dose of glucose in adult is 20 g) or carbohy-
drate containing juices, soft drinks, candy, snacks or a meal 
can effectively ameliorate asymptomatic (detected by self-
monitoring of blood glucose) or mild-moderate symptom-
atic hypoglycemia within 15-20 minutes.25 Parenteral treat-
ment is necessary when a hypoglycemic patient is unwilling 
or unable to take carbohydrates orally. Initial management 
of hypoglycemia consists of administration of 1 g/kg body 
weight dextrose, as D50W in adults. This can be followed 
by infusion of D5W or D10W at a rate maintaining serum 
glucose above 100 mg/dL in certain circumstances. Repeat 
bedside glucose determination should be performed every 
30 min for the first two hours, to detect RH.8,80,81 Glucose 
replacement should be given intravenously in patients treat-
ed with α-glucosidase inhibitors.
Glucagon can cause glycogenolysis but also insulin re-
lease; thus it is most useful in T1DM rather than T2DM pa-Hypoglycemia Revisited 
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lines. Tight glycemic control (between 80-109 mg/dL) is 
associated with a high incidence of hypoglycemia and an 
increased risk of death in patients not receiving parenteral 
nutrition.13,23 Female gender, diabetes history, length of ICU 
stay, and necessity of mechanical ventilation and renal re-
placement are risk factors for the development of hypogly-
cemia.12 Insituting glycemic control and targeting a blood 
glucose level of less than 150 to 180 mg/dL is suggested.23,99
Noncardiogenic pulmonary edema
Pulmonary edema was a well-known complication of insu-
lin-shock therapy for schizophrenia in the past but has be-
come an “ignored complication” in recent years. Severe hy-
poglycemia can cause noncardiogenic pulmonary edema as a 
result of: 1) massive sympathetic nervous system activation 
and its associated hemodynamic alterations; 2) disrupted in-
tegrity of the alveolar epithelium and pulmonary capillary 
endothelium and 3) acute effects of insulin on the cardiovas-
cular system and capillary permeability.100-102
NEUROLOGY
 
Hypoglycemia is known to cause neurologic deficits rang-
ing from reversible focal deficits to irreversible coma. The 
associated neurologic deficits can be attributed to acute brain 
injury, selective neuronal vulnerability, cerebral vasospasm 
and asymmetric cerebral blood flow.103-106 Hypoglycemia 
causes neuronal damage only when the electroencephalog-
raphy becomes flat; this usually occurs after serum glucose 
levels at less than 18 mg/dL for some period. Hypoglyce-
mia often differs from ischemia in its neuropathologic dis-
tribution. White matter is more sensitive to hypoglycemia 
and there is no specific association between the pattern of 
injury and clinical outcomes whether the cerebral cortex, 
deep gray matter, and/or white matter are affected. Involve-
ment of the dentate gyrus of the hippocampus can occur. Dif-
fuse and extensive injury observed on the diffusion-weighted 
images predicts a poor neurologic outcome in patients with 
hypoglycemic injuries.107 However, the cerebellum and 
brainstem are usually universally spared in hypoglycemic 
brain damage.108 Central pontine myelinolysis can be caused 
by hypoglycemia.109 Avoiding treatment-induced hypergly-
cemic overshoots may minimize hypoglycemic brain inju-
ry. Maintaining a normal serum glucose concentration dur-
ing treatment is recommended for treating ischemic brain 
injury.110 Following hypertension and atrial fibrillation, DM 
to elevated blood pressure, increased blood pressure vari-
ability and recurrent rises blood pressure post-hypoglyce-
mia episode may be of concern.91
Ampulla cardiomyopathy
Ampulla cardiomyopathy after hypoglycemic coma was re-
ported in a young female who had anorexia nervosa. Hypo-
glycemia-associated cardiomyopathy can cause reversible 
ventricular dysfunction that requires mechanical support.92,93
Sudden death and “dead in bed” syndrome
Sudden nocturnal death in patients with T1DM is thought 
to be due to nocturnal hypoglycemia-related QT prolonga-
tion with subsequent ventricular tachyarrhythmia.89 Potential 
factors contributing to the increased risk of sudden cardiac 
death observed in patients with DM include silent myocardi-
al ischemia, autonomic nervous system dysfunction, abnor-
mal cardiac repolarization, hypoglycemia, a hypercoagula-
ble state secondary to DM, diabetic cardiomyopathy, and 
impaired respiratory response to hypoxia and hypercapnea.94 
An estimated 2-4% of deaths of patients with T1DM had 
been attributed to hypoglycemia.95
PULMONARY AND CRITICAL  
CARE MEDICINE
 
Pneumonia 
Hypoglycemia was independently associated with increased 
in-hospital, 30-day and 1-year mortality, and with further 
need for mechanical ventilation and inotropic support in pa-
tients presenting with community-acquired pneumonia.96,97
Critical care medicine 
Hyperglycemia during critical illness is common and is as-
sociated with increased mortality. Hyperglycemia is a po-
tentially harmful but correctable metabolic derangement in 
intensive care unit (ICU) patients.86 Even mild or moderate 
hypoglycemia (<81 mg/dL) are associated with increased 
mortality in ICU patients, and hypoglycemia is indepen-
dently associated with increased risk of death, cardiovascu-
lar death, and death due to infectious disease.98 Intensive glu-
cose control in ICU patients has been shown to lower rates 
of mortality in past studies. However, recent systematic re-
view and meta-analysis conclude that there is no evidence 
to support the use of intensive insulin therapy in general-
surgical ICU patients who are fed according to current guide-Shih-Hung Tsai, et al.
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ance of hypoglycemia. 
Other endocrinological emergencies 
Severe hypoglycemia can be the initial clinical presenta-
tion in patients with thyrotoxicosis. In a state of hyperthy-
roidism, facilitated glucose utilization in the presence of hy-
perinsulinemia is not appropriately counter-regulated.114-116 
Hypoglycemia is one of the key features of adrenal insuffi-
ciency. The clinical presentations of adrenal insufficiency can 
range from altered consciousness, hypotension, hypothermia, 
malaise and nausea/vomiting, and cardiac arrhythmia.117
Electrolyte imbalances
Insulin increases skeletal muscle potassium uptake by acti-
vating membrane Na+/K+ ATPase.118 Insulin can also regu-
late phosphorus and magnesium balance.119 Hypoglycemia 
can be complicated by hyponatremia, hypokalemia, hypo-
phosphatemia, and hypomagnesemia.81,120,121 Thus serum 
electrolytes should be carefully monitored in patients with 
severe and prolonged hypoglycemia.
Acute steatosis
Elevated liver enzymes and acute steatosis have also been re-
ported to be associated with hypoglycemia. Excessive carbo-
hydrate and insulin administration can lead to triglyceride ac-
cumulation in the hepatocytes and steatosis as a consequence 
of insufficient exportation of lipids from the liver.122,123
CONCLUSION
Clinicians should have high clinical suspicion of subtle 
symptoms of hypoglycemia and provide prompt treatment. 
Clinicians should be aware that hypoglycemia is associated 
with considerable adverse outcomes in many acute critical 
illnesses. To reduce hypoglycemia-associated morbidity 
and mortality, a timely health education programme and 
close monitoring should be applied to those diabetic patients 
presenting to the Emergency Department with SH. ED dis-
position strategies should be further validated and justified 
to achieve balance between the benefits from euglycemia 
and the risks of SH. 
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is the third prevalent risk factor (14.5%) for acute ischemic 
stroke in the Acute STroke Registry and the Analysis of Lau-
sanne study.111 A J-shaped association can be found between 
serum glucose levels at admission and functional outcomes, 
indicating that hypoglycemia is of similar importance to 
hyperglycemia for stroke prognosis. This study defines a 
range of serum glucose levels at admission between 67-132 
mg/dL as being associated with long-term favorable out-
comes (12 months after stroke).16 Therefore, hypoglycemia 
and hyperglycemia should both be prevented and treated 
with similar effort and attention. 
METABOLISM/ ENDOCRINOLOGY
Hypoglycemia associated autonomic failure 
Hypoglycemia associated autonomic failure (HAAF) is a 
functional disorder manifested clinically by recurrent iatro-
genic hypoglycemia. It is a dynamic phenomenon that can 
be induced by prior hypoglycemic episodes and reversed 
by 2-3 weeks avoidance of hypoglycemia in most affected 
patients.26 The clinical impact of HAAF is well established 
in patients with T1DM, but it also affects patients with ad-
vanced T2DM. The prevalence of IAH in insulin-treated 
T2DM was associated with higher frequencies of biochem-
ical hypoglycemia and SH.112 Episodes of hypoglycemia, 
even asymptomatic episodes, impair defenses against sub-
sequent hypoglycemia by causing HAAF. The clinical syn-
dromes of hypoglycemia unawareness and defective glu-
cose counterregulation beget a vicious cycle of repeated 
hypoglycemic episodes.5 The two main components of 
HAAF are reduced counterregulatory hormone responses 
and lack of awareness of hypoglycemia.
Defective glucose counterregulation
Loss of the glucagon secretory response, a key feature of 
defective glucose counterregulation, can be explained by 
insulin deficiency; specifically, loss of the decrement in in-
traislet insulin that normally signals glucagon secretion as 
glucose levels fall.5 
Impaired awareness of hypoglycemia
Reduced neurogenic symptoms are largely the result of re-
duced sympathetic neural responses to falling glucose lev-
els. Impaired awareness of hypoglycemia developed in 19.5 
to 25% of patients with T1DM.113 It is potentially reversible, 
either by relaxing glycemic control or by complete avoid-Hypoglycemia Revisited 
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